KR20170118624A - Method for extracting soluble curcuminoid from turmericand soluble curcuminoid extracted by the same - Google Patents
Method for extracting soluble curcuminoid from turmericand soluble curcuminoid extracted by the same Download PDFInfo
- Publication number
- KR20170118624A KR20170118624A KR1020170049391A KR20170049391A KR20170118624A KR 20170118624 A KR20170118624 A KR 20170118624A KR 1020170049391 A KR1020170049391 A KR 1020170049391A KR 20170049391 A KR20170049391 A KR 20170049391A KR 20170118624 A KR20170118624 A KR 20170118624A
- Authority
- KR
- South Korea
- Prior art keywords
- cucuminoids
- ethanol
- soluble
- water
- extracted
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 229930153442 Curcuminoid Natural products 0.000 title claims description 4
- 235000019202 steviosides Nutrition 0.000 claims abstract description 93
- 239000004383 Steviol glycoside Substances 0.000 claims abstract description 68
- 235000019411 steviol glycoside Nutrition 0.000 claims abstract description 68
- 229930182488 steviol glycoside Natural products 0.000 claims abstract description 68
- 150000008144 steviol glycosides Chemical class 0.000 claims abstract description 68
- 239000008280 blood Substances 0.000 claims abstract description 11
- 210000004369 blood Anatomy 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 106
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 39
- 238000000605 extraction Methods 0.000 claims description 32
- 229940013618 stevioside Drugs 0.000 claims description 24
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 23
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 23
- 235000012754 curcumin Nutrition 0.000 claims description 19
- 239000004148 curcumin Substances 0.000 claims description 19
- 229940109262 curcumin Drugs 0.000 claims description 19
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 19
- 229930182480 glucuronide Natural products 0.000 claims description 16
- 150000008134 glucuronides Chemical class 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 102000053187 Glucuronidase Human genes 0.000 claims description 11
- 108010060309 Glucuronidase Proteins 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 7
- 229930182478 glucoside Natural products 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 238000006911 enzymatic reaction Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- CANAPGLEBDTCAF-QHSHOEHESA-N Dulcoside A Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2O[C@]34CC[C@H]5[C@]6(C)CCC[C@](C)([C@H]6CC[C@@]5(CC3=C)C4)C(=O)O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H](O)[C@H]1O CANAPGLEBDTCAF-QHSHOEHESA-N 0.000 claims description 2
- CANAPGLEBDTCAF-NTIPNFSCSA-N Dulcoside A Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@]23C(C[C@]4(C2)[C@H]([C@@]2(C)[C@@H]([C@](CCC2)(C)C(=O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)CC4)CC3)=C)O[C@H](CO)[C@@H](O)[C@@H]1O CANAPGLEBDTCAF-NTIPNFSCSA-N 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 150000008131 glucosides Chemical class 0.000 claims description 2
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 50
- 230000000694 effects Effects 0.000 abstract description 15
- 230000003078 antioxidant effect Effects 0.000 abstract description 10
- 230000005764 inhibitory process Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 9
- 239000003021 water soluble solvent Substances 0.000 abstract description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 7
- 239000008103 glucose Substances 0.000 abstract description 7
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 229940126601 medicinal product Drugs 0.000 abstract description 2
- 239000002195 soluble material Substances 0.000 abstract description 2
- 244000163122 Curcuma domestica Species 0.000 description 35
- 235000003373 curcuma longa Nutrition 0.000 description 34
- 235000003392 Curcuma domestica Nutrition 0.000 description 31
- 235000013976 turmeric Nutrition 0.000 description 31
- 239000000843 powder Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 229930188195 rebaudioside Natural products 0.000 description 8
- 241000954177 Bangana ariza Species 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000002292 Radical scavenging effect Effects 0.000 description 6
- 229940032084 steviol Drugs 0.000 description 6
- 241000725619 Dengue virus Species 0.000 description 5
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 240000008067 Cucumis sativus Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- -1 Steviol glucoside Chemical class 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 2
- 239000001512 FEMA 4601 Substances 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000863498 Urophyllum Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 235000019203 rebaudioside A Nutrition 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 235000009849 Cucumis sativus Nutrition 0.000 description 1
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000710844 Dengue virus 4 Species 0.000 description 1
- 229930186291 Dulcoside Natural products 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- YWPVROCHNBYFTP-UHFFFAOYSA-N Rubusoside Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1O YWPVROCHNBYFTP-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940102465 ginger root Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical group COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- YWPVROCHNBYFTP-OSHKXICASA-N rubusoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YWPVROCHNBYFTP-OSHKXICASA-N 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/87—Preparation of ketenes or dimeric ketenes
- C07C45/90—Separation; Purification; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/225—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2112—Curcumin, turmeric
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법 및 이에 의하여 추출된 수용성이 증가된 커큐미노이드에 관한 것이다.
본 발명의 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법에 의하여 추출된 수용성이 증가된 커큐미노이드는 본래 난용성 소재인 커큐미노이드의 수용성 용매에 대한 용해성이 개선될 뿐만 아니라, 수용성 용매에 용해된 커큐미노이드는 커큐미노이드의 원래 효과, 예를 들면 항산화 작용 및 혈당 상승 억제 작용을 효과를 충분히 얻을 수 있으므로, 식품, 의약용품 그리고 화장품의 소재로서 유용하게 사용될 수 있다.The present invention relates to a method for extracting an increased water-soluble cucuminoid using a steviol glycoside and to an increased water-soluble cucuminoid extracted therefrom.
The cucuminoids having increased water solubility extracted by the method of extracting cucuminoids with increased water solubility using the steviol glycoside of the present invention not only improve the solubility of the cucuminizoid, which is a poorly soluble material, in a water-soluble solvent, Cucuminizoid dissolved in a water-soluble solvent can be effectively used as a material for foods, medicinal products, and cosmetics since the original effect of cucuminoids, for example, antioxidative action and inhibition of blood glucose elevation can be sufficiently obtained.
Description
본 발명은 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법 및 이에 의하여 추출된 수용성이 증가된 커큐미노이드에 관한 것이다. 본 발명의 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법에 의하여 추출된 수용성이 증가된 커큐미노이드는 본래 난용성 소재인 커큐미노이드의 수용성 용매에 대한 용해성이 개선될 뿐만 아니라, 물에 용해된 커큐미노이드는 수용액 내에서 커큐미노이드의 원래 효과, 예를 들면 항산화 작용 및 혈당 상승 억제 작용을 효과를 충분히 얻을 수 있으므로, 식품, 의약용품 그리고 화장품의 소재로서 유용하게 사용될 수 있다.The present invention relates to a method for extracting an increased water-soluble cucuminoid using a steviol glycoside and to an increased water-soluble cucuminoid extracted therefrom. The cucuminoids having increased water solubility extracted by the method of extracting cucuminoids with increased water solubility using the steviol glycoside of the present invention not only improve the solubility of the cucuminizoid, which is a poorly soluble material, in a water-soluble solvent, Cucuminizoid dissolved in water can be used effectively as a material for foods, medicinal products and cosmetics since it can sufficiently obtain the effect of the original effect of the cucuminoids in aqueous solution, for example, antioxidative action and inhibition of blood glucose elevation .
커큐미노이드는 동인도산의 생강과에 속하는 식물인 Curcuma longa Linn(Zingiberaceae)의 뿌리에서 추출된 폴리페놀 성분의 노란색 향신료로 aromatic methoxy phenol groups, α, β-unsaturated β-diketo linker, 케토-엔올 상호변이성(keto-enol tautomerism) 등 세 가지 주요 화학기능으로 인하여 신경계 보호, 항당뇨, 항암, 심장계 보호 등 복합표적(multi-targeted) 생체기능성을 갖고 있어 다양한 만성질환에 대한 치료제나 예방제의 소재로서 식품뿐 아니라 의약학계에서 활발한 연구개발이 진행되고 있다. Cucuminoids are yellow spices of polyphenol component extracted from the roots of Curcuma longa Linn (Zingiberaceae), a plant belonging to the ginger family of the Dong-dong Province, and aromatic methoxy phenol groups, α, β-unsaturated β-diketo linker, Due to its three main chemical functions including keto-enol tautomerism, it has multi-targeted biofunctions such as nervous system protection, anti-diabetic, anticancer, cardioprotection, and is a therapeutic and preventive agent for various chronic diseases. Active research and development are underway in the field of medicine as well as food.
그러나, 커큐민은 물을 기준으로 ml 당 0.1 mg 미만, 구체적으로는 11~600 ng/ml의 용해도를 갖는 난용성 물질로서, 일반적으로 물질은 용해되어 있는 상태에서 생리작용을 나타낼 수 있으므로 가용화는 그 효과에 밀접한 관계를 가지며, 이는 그 물질의 이용에 있어 중요한 성질이다. 그렇기에 커큐민과 같은 난용성 물질의 경우에는 가용화가 필수적이다. However, curcumin is an insoluble substance having a solubility of less than 0.1 mg / ml, specifically 11 to 600 ng / ml, based on water. In general, since the substance may exhibit a physiological action in a dissolved state, It is closely related to the effect, which is an important property in the use of the substance. Therefore, solubilization is indispensable for weakly soluble substances such as curcumin.
또한 일반적으로 커큐미노이드는 pH 7.2 이상의 알카리 조건에서 매우 불안정하여 30분 가량 보관하면 90% 이상 분해되고(Stability of curcumin in buffer solutions and characterization of its degradation products. Journal of Pharmaceutical and Biomedical Analysis, 15, 1867-1876), 산성 조건에서는 물에 녹지를 않으면서 쉽게 분해가 되는 것으로 알려져 있으며(Kinetics of alkaline degradation of the food pigments curcumin and curcuminoids. Journal of Food Science, 62, 267-269), pH 7.4에서 10분 뒤 90%의 커큐미노이드가 분해된다는 연구 결과도 있다. Also typically increases kyumi solenoid when very unstable in alkaline conditions pH above 7.2, kept for about 30 minutes and decomposition over 90% (Stability of curcumin in buffer solutions and characterization of its degradation products. Journal of Pharmaceutical and Biomedical Analysis, 15, 1867 (Kinetics of alkaline degradation of the food pigments curcumin and curcuminoids. Journal of Food Science, 62 , 267-269), pH 7.4 for 10 minutes Studies have also shown that 90% of glucuronidase is degraded.
또한 일반적으로 커큐미노이드는 체내에서도 낮은 장내 투과도를 보인다. 커큐미노이드의 겉보기 세포 투과도는 약 3x10-6 cm/s로서 매우 낮은데 이러한 낮은 투과도는 10% 이상의 커큐미노이드가 세포투과 중 대사되어 분해되며 20% 이상이 세포 내에 축적되어 버리기 때문인 것으로 알려져 있다. In addition, cucuminoids generally exhibit low intestinal permeability in the body. The apparent cellular permeability of cucuminoids is very low, about 3 × 10 -6 cm / s, which is known to be due to the fact that more than 10% of the cucuminoids are degraded by metabolism during cell permeation and more than 20% are accumulated in the cells.
이와 같은 이유로 인하여 구강 섭취의 경우, 커큐미노이드 생체 이용률 (bioavailability)은 1% 미만인 것으로 알려져 있어 이용성을 증가시키기 위한 다양한 방법이 연구 및 제시되고 있다. 대한민국 등록특허 10-1258537에서는 수용성 및 안정성을 개선한 신규 커큐민 유도체를 개시하고 있으나, 이는 여러 단계를 통한 화학적 합성을 거친다는 점에서 상업적 효율성에 한계가 있다고 할 수 있다. For these reasons, bioavailability of cucuminoids is less than 1% in the case of oral ingestion, and various methods for increasing the bioavailability have been studied and suggested. Korean Patent No. 10-1258537 discloses a novel curcumin derivative that improves water solubility and stability, but it has a limited commercial efficiency because it undergoes chemical synthesis through various steps.
울금 (강황; Curcuma longa L.)은 생강과에 속하는 향신료 및 천연색소로서 전통적으로 안전하게 사용되어온 식품소재이다. 치매예방, 간질환, 우울증, 위장질환 치료, 숙취해소, 변비예방 목적으로 전통적으로 인도를 비롯한 아시아에서 널리 사용되어 왔으며 한약재의 주요 소재로서 사용되고 있다. 항염, 혈당상승억제, 항산화, 항균, 항암 작용을 하며, 심혈관 질환, 대사질환, 자가 면역질환 등 다양한 생리활성효과가 있는 것으로 알려져 있기 때문에 캡슐, 연고, 에너지 음료, 생활용품, 화장품 등 다양한 제품의 소재로 활용되고 있다. 또한, 최근에는 알츠하이머, 뇌손상 보호, 혈관성 치매, 당뇨 등에 효과가 있는 것으로 알려지는 등 기능성 소재로서 주목받고 있다. 이러한 효능을 나타내는 이유는 울금의 노란색 색소성분인 커큐미노이드(curcuminoid) 때문이며, 그 주요 성분은 커큐민(curcumin)으로 알려져 있다. Curcuma longa L.) is a food material that has traditionally been safely used as a spice and natural coloring agent in the ginger root. It has been widely used in India and other Asian countries for the prevention of dementia, liver disease, depression, treatment of gastrointestinal diseases, relieving hangover, and preventing constipation. It is known that it has anti-inflammatory, anti-inflammatory, anti-inflammatory, antioxidant, antimicrobial and anti-cancer effects and various physiological activity effects such as cardiovascular diseases, metabolic diseases and autoimmune diseases. Therefore, various products such as capsules, ointments, energy drinks, It is utilized as material. In recent years, it has been attracting attention as a functional material known to be effective for Alzheimer's disease, brain damage protection, vascular dementia, diabetes and the like. The reason for this effect is due to the curcuminoid, a yellow coloring matter of Ulgum, and its major component is known as curcumin.
커큐미노이드(curcuminoid)는 강황(울금) 의 뿌리에 2-6% 함유되어 있으며, 그 대부분은 커큐민으로 구성되어 있으나 약 17%의 디메톡시 커큐민(demethoxy curcumin)과 3%의 비스디메톡시 커큐민(bisdemethoxy curcumin) 형태로도 포함된다. 식약처에서는 커큐마 롱가의 뿌리 줄기를 강황, 덩이뿌리를 울금으로 규정하고 있다. 즉, 강황과 울금은 같은 식물의 뿌리이지만, 줄기와 이어져 있는 뿌리를 강황, 강황 아래쪽으로 이어져 작게 달려 있는 것을 울금이라고 한다. Curcuminoids are 2-6% in the roots of turmeric, and most of them are composed of curcumin, but about 17% of demethoxy curcumin and 3% of bisdimethoxy curcumin bisdemethoxy curcumin). At the hospital, the rootstock of curcuma longa is designated as turmeric, and the root of root is called turmeric. In other words, turmeric and turmeric are the roots of the same plant, but they are called turmeric, which is tied to the bottom of the turmeric and turmeric troughs.
한편, 스테비올 배당체는 천연첨가물로 분류되는 감미료로, 국화과 스테비아의 잎에서 추출하여 제조된다. 감미도는 설탕의 약 200~300배이다. 스테비아는 남미의 파라과이 원산 식물로, 현지인들은 오래전부터 건조한 잎을 감미제로 이용하여 왔다. 현재 저칼로리식품, 탄산음료, 과자, 절임 식품 등에 사용되고 있다. JECFA(합동식품첨가물 전문가위원회)에서 안전성 평가 결과, 1일 섭취허용량(ADI)은 0~4mg/kg·체중/일(스테비올)로 설정되어 있다. 스테비올 배당체의 종류로는 스테비오사이드(stevioside), 리바우디오사이드(rebaudioside), 둘코사이드(dulcoside), 루부소사이드(rubusoside), 스테비올사이드(steviolside) 등이 존재한다. On the other hand, steviol glycoside is a sweetener classified as a natural additive, and is produced by extracting from leaves of Chrysanthemum and Stevia. The sweetness is about 200 ~ 300 times of sugar. Stevia is native to Paraguay in South America, and locals have long been using dried leaves as sweeteners. It is currently used in low-calorie foods, carbonated drinks, confectionery, pickles, and the like. JECFA (Joint Food Additives Expert Committee), the result of safety evaluation, the allowable daily intake (ADI) is set at 0 ~ 4mg / kg, weight / day (steviol). The steviol glycosides include stevioside, rebaudioside, dulcoside, rubusoside, steviolside, and the like.
선행문헌Precedent literature
1. 대한민국 등록특허 10-12585371. Korean Patent No. 10-1258537
2. 대한민국 공개특허 10-2015-642342. Korean Patent Publication No. 10-2015-64234
본 발명자들은 스테비올 배당체를 이용하여 커큐미노이드를 추출하는 경우 수용성 용매에 대한 커큐미노이드의 수용해성이 현저히 개선되어 직접 추출될 수 있음을 발견하고, 본 발명을 완성하였다. The inventors of the present invention discovered that when water extracts curcuminoids using steviol glycosides, the water solubility of the curcuminoids in the water-soluble solvent is remarkably improved and can be directly extracted, thus completing the present invention.
일 구현예에 따르면,According to one embodiment,
(a) 커큐민 포함 원재료와 스테비올 배당체를 혼합하는 단계; (a) mixing a raw material containing curcumin and a steviol glycoside;
(b) 상기 혼합물을 에탄올에 용해시키고 교반하는 단계; (b) dissolving the mixture in ethanol and stirring;
(c) 상기 에탄올에 용해된 혼합물을 원심분리시키는 단계; (c) centrifuging the mixture dissolved in ethanol;
(d) 상층액을 분리 제거하는 단계; 및(d) separating and removing the supernatant; And
(e) 분리된 상층액에 포함된 에탄올을 제거하여 커큐미노이드를 수득하는 단계; 를 포함하는 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법이 개시된다. (e) removing the ethanol contained in the separated supernatant to obtain a cucuminoid; A method of extracting an increased water-soluble cucuminoid using a steviol glycoside comprising
본 발명에서 "용해"는 물에 완전히 녹는 상태뿐만 아니라 미셀 등에 의한 가용화 상태, 또는 수성 용매 중에 균일하게 분산되어 육안으로 투명한 액의 상태를 포함하며, 각 물질의 용해도 측정에 일반적으로 사용되는 시험 방법으로 측정되는 상태를 의미한다. In the present invention, "dissolution" includes not only a state of being completely dissolved in water but also a state of being solubilized by micelles or the like, or a state of a liquid being visually dispersed uniformly in an aqueous solvent, As shown in FIG.
본 발명에서 "수용성이 증가된"의 의미는 증류수 등과 같은 수용성 용매에 대한 용해도가 증가되었다는 것을 의미한다. 본 발명에서 "수용성이 증가된" 커큐미노이드는 커큐미노이드와 스테비올 배당체의 복합체를 의미하며, 커큐미노이드와 스테비올 배당체의 복합체는 상기와 같이 에탄올에 스테비올 배당체와 혼합 후 원심분리하는 추출 과정을 통해 커큐미노이드와 스테비올 배당체 사이에 명확한 공유결합이 형성되지는 않으나, 분자간 결합에 의해 물리적으로 일정구조를 형성하는 상태를 의미한다.In the present invention, "increased water solubility" means that solubility in a water-soluble solvent such as distilled water is increased. In the present invention, "increased water solubility" refers to a complex of a cucuminoid and a steviol glycoside, and a complex of a cucuminoid and a steviol glycoside is prepared by mixing ethanol with a steviol glycoside and then centrifuging The extraction process does not form a clear covalent bond between the cucuminoids and the steviol glycosides, but it means a state in which a physically constant structure is formed by intermolecular bonding.
본 발명에 따른 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법에 의해서 상기 울금 또는 강황으로부터 추출되는 커큐미노이드는 소재는 15% 이상, 50% 이상, 60% 이상, 80% 이상 수용화되거나 실질적으로 전부 수용상태가 될 수 있다.According to the method of extracting cucuminoids with increased water solubility using steviol glycosides according to the present invention, the content of cucuminoids extracted from the cucumbers or turmeric is 15% or more, 50% or more, 60% or more, 80% or more Or substantially entirely in a receiving state.
본 발명에 따른 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법에 있어서, 상기 커큐민 포함 원재료는 울금 또는 강황 일 수 있다. 식약처에서는 커큐마 롱가의 뿌리 줄기를 강황, 덩이뿌리를 울금으로 규정하고 있다. 즉, 강황과 울금은 같은 식물의 뿌리이지만, 줄기와 이어져 있는 뿌리를 강황, 강황 아래쪽으로 이어져 작게 달려 있는 것을 울금이라고 한다. In the method of extracting an increased water-soluble glucuronidase using a steviol glycoside according to the present invention, the curcumin-containing raw material may be Ulugum or turmeric. At the hospital, the rootstock of curcuma longa is designated as turmeric, and the root of root is called turmeric. In other words, turmeric and turmeric are the roots of the same plant, but they are called turmeric, which is tied to the bottom of the turmeric and turmeric troughs.
본 발명에 따른 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법에 있어서, 상기 울금 또는 강황은 분말 상태거나, 원재료 그대로의 상태를 모두 이용하는 것이 가능하다. 울금 또는 강황의 분말은 생울금 또는 강황을 분쇄시켜서 제조되며, 제조 방법이 특별히 제한되는 것은 아니다. In the method of extracting glucuronidase with increased water solubility using the steviol glycoside according to the present invention, it is possible to use all of the above-mentioned uroguanum or turmeric in a powder state or a raw material state as it is. The powder of urea or of turmeric is prepared by pulverizing raw coriander or turmeric, and the production method is not particularly limited.
본 발명에 따른 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법에 있어서, 에탄올에 용해되는 울금은 농도가 40% (w/v) 이하인 것이 바람직하다. 울금의 농도가 40% (w/v)를 초과하는 경우, 울금의 함량 증가에 따른 커큐미노이드의 추출량의 유의적인 차이가 존재하지 않는다. In the method for extracting the increased water-soluble glucuronide using the steviol glycosides according to the present invention, it is preferable that the concentration of the wort silver dissolved in ethanol is 40% (w / v) or less. There is no significant difference in the amount of curcuminoids extracted when the concentration of ugum exceeds 40% (w / v).
본 발명에 따른 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법에 있어서, 상기 스테비올 배당체는 스테비오사이드 (stevioside), 리바우디오사이드 A, 리바우디오사이드 B, 리바우디오사이드 C, 리바우디오사이드 D, 리바우디오사이드 E, 루부소사이드, 둘코사이드 A, 스테비올사이드 또는 이들의 혼합물일 수 있다. In the method of extracting cucuminoids with increased water solubility using the steviol glycoside according to the present invention, the steviol glycoside is selected from the group consisting of stevioside, ribauidoside A, ribauidoside B, ribauidoside C , Ribauidoside D, ribauidoside E, rubusoidal, dulcoside A, steviolide, or a mixture thereof.
본 발명에 따른 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법에 있어서, 에탄올에 용해되는 스테비올 배당체의 농도는 5-10%(w/v)일 수 있다. 바람직하기는, 상기 스테비올 배당체의 농도는 8%(w/v)일 수 있다.In the method for extracting the increased water-soluble glucuronidase using the steviol glycoside according to the present invention, the concentration of the steviol glycoside dissolved in ethanol may be 5-10% (w / v). Preferably, the concentration of the steviol glycoside may be 8% (w / v).
본 발명에 따른 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법에 있어서, 상기 스테비올 배당체는 정제된 것이거나 효소 반응산물인 것일 수 있다. 즉, 본발명에 있어서, 스테비올 배당체 자체를 사용하거나, 스테비올 배당체 효소 반응액을 모두 사용하는 것이 가능하다. 일 구현예에 따르면, 상기 효소는 락타아제인 것이 가능하다.In the method for extracting increased water-soluble glucuronides using the steviol glycoside according to the present invention, the steviol glycosides may be purified or enzymatic reaction products. That is, in the present invention, it is possible to use the steviol glycoside itself, or to use all of the steviol glycoside enzyme reaction solution. According to one embodiment, it is possible that the enzyme is lactase.
본 발명에 따른 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법에 있어서, 상기 에탄올은 80 내지 90 % 에탄올 용액을 나타내는 것일 수 있다. In the method for extracting the increased water-soluble glucuronide using the steviol glycosides according to the present invention, the ethanol may be an 80 to 90% ethanol solution.
본 발명에 따른 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법에 있어서, 상기 혼합물을 에탄올에 용해시키고 교반하는 단계는 10분 내지 20분 동안 수행될 수 있다. 상기 혼합시간이 10분 이하일 경우 복합체 형성을 위한 충분한 반응이 일어나지 못하며, 상기 혼합 시간이 20분 이상일 경우 불필요한 혼합과정으로 반응효율이 저하될 수 있다. In the method of extracting water-soluble glucuronides with steviol glycosides according to the present invention, the step of dissolving the mixture in ethanol and stirring may be carried out for 10 minutes to 20 minutes. When the mixing time is less than 10 minutes, sufficient reaction for forming the complex does not occur. If the mixing time is more than 20 minutes, the reaction efficiency may be lowered due to unnecessary mixing process.
본 발명은 또한, 본 발명에 따른 스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법에 의하여 추출된 커큐미노이드를 제공한다. The present invention also provides a glucuronide extracted by the method of extracting the increased water-soluble glucuronidase using the steviol glycoside according to the present invention.
본 발명에 따른 스테비올 배당체를 이용하여 추출된 수용성이 증가된 커큐미노이드는 의약품, 동물용 의약품, 의약부외품, 화장품 및 농약 중 어느 하나의 유효 성분이 되는 물질 또는 식품 첨가물일 수 있다.The cucuminizoid having increased water solubility extracted using the steviol glycoside according to the present invention may be a substance or a food additive which becomes an active ingredient of any one of medicines, veterinary medicines, quasi drugs, cosmetics and pesticides.
본 발명에 의한 추출 방법에 의하여 추출된 수용성이 증가된 커큐미노이드는 항산화 작용 및/또는 혈당상승 억제 작용 효과를 가질 수 있다. The increased water-soluble glucuronide extracted by the extraction method according to the present invention may have an antioxidant activity and / or an effect of inhibiting the increase of blood sugar.
본 발명에 의한 추출 방법에 의하여 추출된 수용성이 증가된 커큐미노이드는 뎅기열 바이러스의 활성 저해 특성을 가질 수 있다. The increased water-soluble curcuminoids extracted by the extraction method according to the present invention may have a property of inhibiting the activity of dengue virus.
본 발명에 의한 추출 방법에 의하여 추출된 수용성이 증가된 커큐미노이드는 수용성 용매에 대한 용해성이 개선되어 원래 커큐미노이드가 발휘하지 못했던 효과를 충분히 얻을 수 있다. 또한, 본 발명의 커큐미노이드의 수용해성 개선 방법은 생산성, 비용의 측면에서 우위에 있으며, 작업자의 안전성이 우수하고, 공업적 이용가치가 높다.The increased solubility of the water-soluble glucuronide by the extraction method according to the present invention improves the solubility in a water-soluble solvent, so that the effect that the original glucuronide did not exert can be sufficiently obtained. Further, the method of improving water solubility of the cucuminoids of the present invention is superior in terms of productivity and cost, has excellent safety of workers, and has high industrial value.
도 1은 본 발명의 일 실시예에서 추출된 커큐미노이드의 용해도를 측정한 결과를 나타낸다.
도 2는 본 발명의 일 실시예에서 추출된 커큐미노이드를 용해시킨 수용액에 대한 얇은 막크로마토그래피 결과를 나타낸다.
도 3은 본 발명의 일 실시예에서 에탄올 용액 중 물의 양에 따른 수용화된 커큐미노이드의 추출 효율을 나타낸다.
도 4는 본 발명의 일 실시예에서 첨가되는 스테비올 배당체의 농도에 따른 수용화된 커큐미노이드의 추출 효율을 나타낸다.
도 5 및 6은 본 발명의 일 실시예에서 첨가되는 울금의 농도에 따른 수용화된 커큐미노이드의 추출 효율을 나타낸다.
도 7 및 도 8은 본 발명의 일 실시예에서 추출된 커큐미노이드의 DPPH 활성을 측정한 결과를 나타낸다.
도 9는 본 발명의 일 실시예에 의하여 추출된 커큐미노이드 입자의 크기를 측정한 결과를 나타낸다.
도 10은 본 발명의 일 실시예에 의하여 추출된 커큐미노이드 투여 후 시간별 혈당의 변화를 나타낸다.
도 11은 본 발명의 일 실시예에 의하여 추출된 커큐미노이드의 뎅기 바이러스의 활성 저해 정도를 측정한 결과를 나타낸다.Figure 1 shows the results of measuring the solubility of the extracted glucuronides in one embodiment of the present invention.
Figure 2 shows thin film chromatographic results for an aqueous solution of the extracted glucuronidase in one embodiment of the present invention.
Figure 3 shows the extraction efficiency of water-soluble glucocinoids according to the amount of water in the ethanol solution in one embodiment of the present invention.
Figure 4 shows the extraction efficiency of the water-soluble glucuronide according to the concentration of the steviol glycoside added in one embodiment of the present invention.
Figures 5 and 6 show the extraction efficiencies of the water-soluble glucocinoids according to the concentration of urea added in one embodiment of the present invention.
Figures 7 and 8 show the results of measuring DPPH activity of the extracted glucuronidase in one embodiment of the present invention.
9 shows the results of measuring the size of the carcuminoid particles extracted according to an embodiment of the present invention.
FIG. 10 shows changes in blood glucose level after the administration of glucuronide extracted according to an embodiment of the present invention.
FIG. 11 shows the results of measurement of the degree of inhibition of dengue virus activity of the curcuminoids extracted according to one embodiment of the present invention.
이하, 발명의 이해를 돕기 위해 다양한 실시예를 제시한다. 하기 실시예는 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐 발명의 보호범위가 하기 실시예에 한정되는 것은 아니다.Hereinafter, various embodiments are provided to facilitate understanding of the present invention. The following examples are provided to facilitate understanding of the invention and are not intended to limit the scope of the invention.
<< 실시예Example 1> 스테비올 배당체를 이용한 1> Using steviol glycosides 울금의Ulgum 추출 extraction
울금 가루 300 ㎎을 에탄올 1 ㎖ 에 용해시켜서 30% 울금 에탄올 용액을 제조하고, 스테비올 배당체로서 스테비오사이드와 리바우디오사이드 각각 100 ㎎을 에탄올 1 ㎖ 에 용해시켜서 10% w/v 농도의 스테비올 배당체 에탄올 용액을 제조하였다.300 mg of corn gluten powder was dissolved in 1 ml of ethanol to prepare a 30% corn ethanol solution, and 100 mg of stevioside and ribaudioside as steviol glycosides were dissolved in 1 ml of ethanol to prepare a steviol A glycoside ethanol solution was prepared.
상기 용액을 혼합하여 스테비오 사이드와 울금 가루를 혼합한 경우(Tum-Ste), 및 리바우디오사이드와 울금 가루를 혼합한 경우(Tum-RebA)를 각각 에펜도르프 튜브에 넣고, 에탄올 용액을 넣어 충분히 교반하였다. The above solutions were mixed to prepare an Eppendorf tube, which was prepared by mixing stevioside and turmeric powder (Tum-Ste), and mixing rebaudioside and turmeric powder (Tum-RebA) Lt; / RTI >
교반된 용액을 12,000 rpm에서 10 분 동안 원심분리하고, 상층의 맑은 액을 다른 에펜도르프 튜브에 옮긴 후, 에탄올을 증발시켜서 분말 상태로 수득하였다. The stirred solution was centrifuged at 12,000 rpm for 10 minutes, and the clear solution of the upper layer was transferred to another Eppendorf tube, and the ethanol was evaporated to give a powder.
비교예로서 울금가루를 증류수로만 녹이는 경우(Tum-Water)와 울금 가루를 100% 에탄올만으로 녹이는 경우(Tum-Ethanol)를 같은 과정을 통해 준비하고, 상층의 맑은 액을 회수하여 에탄올을 증발시키고, 남은 것을 다시 물(Tum-Water의 경우) 혹은 에탄올(Tum-Ethanol의 경우)에 녹여 준비하였다. As a comparative example, Tum-Water and Tum-Ethanol were dissolved in distilled water alone (Tum-Water) and 100% ethanol (Tum-Ethanol) were prepared in the same manner. The clear solution of the upper layer was recovered to evaporate ethanol, The remainder was again dissolved in water (for Tum-Water) or ethanol (for Tum-Ethanol).
<< 실험예Experimental Example 1> 추출된 1> extracted 커큐미노이드의Cucuminoid 수용해도 측정 Water solubility measurement
에탄올을 증발시키고 남은 울금 가루를 수용성 용매로서 1 ㎖ 증류수(Tum-Ste, Tum-RebA, Tum-SG의 경우)에 녹이고, 12,000 rpm 으로 10 분 동안 원심분리하고, 맑은 상등액은 0.20 ㎛ membrane 필터(Agilent, Santa clara, CA, USA)를 이용하여 상층의 용액만 회수 하여 울금의 용해 여부를 육안으로 확인하고 그 결과를 도 1에 나타내었다. Ethanol was evaporated and the remaining ugly powder was dissolved in 1 ml of distilled water (for Tum-Ste, Tum-RebA and Tum-SG) as a water-soluble solvent and centrifuged at 12,000 rpm for 10 minutes. The clear supernatant was filtered through a 0.20 ㎛ membrane filter Agilent, Santa Clara, Calif., USA). The results are shown in FIG.
도 1은 각각 다음과 같다. 1 is as follows.
Ste: Stevioside 수용액Ste: Stevioside aqueous solution
RebA: Rebaudioside A 수용액RebA: Rebaudioside A aqueous solution
SG: Steviol glycoside(스테비올 배당체) 수용액SG: Steviol glycoside aqueous solution
Tume-Ste: 울금 가루를 스테비오사이드와 함께 에탄올에 녹이고, 이후 에탄올을 증발시켜 얻은 추출물을 물에 녹인 시료Tume-Ste: A sample obtained by dissolving ugly powder with stevioside in ethanol, and then evaporating the ethanol to obtain an extract
Tum-RebA: 울금 가루를 리바우디오사이드 A와 함께 에탄올에 녹이고, 이후 에탄올을 증발시켜 얻은 추출물을 물에 녹인 시료Tum-RebA: A sample obtained by dissolving Ulymum powder together with Riboidoside A in ethanol, and then evaporating the ethanol to obtain an extract obtained by dissolving the extract in water
Tume-SG: 울금 가루를 스테비올 배당체와 함께 에탄올에 녹이고, 이후 에탄올을 증발시켜 얻은 추출물을 물에 녹인 시료Tume-SG: A sample obtained by dissolving Ulyumus powder with ethanol with steviolglycoside and then evaporating the ethanol.
Tum-water: 울금 가루를 에탄올로 추출하고 이후 에탄올을 증발시켜 얻은 추출물을 물에 녹인 시료Tum-water: A sample obtained by extracting the ugly powder with ethanol and then evaporating the ethanol with water
Tum-Ethanol: 울금가루를 에탄올로 추출하고 이후 에탄올을 증발시켜 얻은 추출물을 에탄올에 녹인 시료Tum-Ethanol: A sample obtained by extracting the ugly powder with ethanol and then evaporating the ethanol with ethanol
도 1에서 보는 바와 같이 울금이 물에서는 거의 용해되지 않으나, 에탄올에는 녹는 것이 있고(Tum-Ethanol), 스테비오사이드, 리바우디오사이드 및 스테비올 배당체를 처리하여 준비한 것은 물에 잘 용해됨이 관찰되었다. 특히, 도 1에서 보는 바와 같이 에탄올 만을 처리(Tum-Ethanol)한 경우에 비해 스테비오사이드(Tum-Ste), 리바우디오사이드(Tum-RebA) 및 스테비올 배당체(Tum-SG)를 혼합하여 에탄올과 함께 처리한 경우 수용성 용매인 물에 대한 울금의 용해가 잘 이루어졌음이 확인되었다.As shown in FIG. 1, it was observed that water was hardly soluble in water, but soluble in ethanol (Tum-Ethanol), stevioside, rebaudioside, and steviol glycoside prepared and dissolved in water . In particular, as shown in FIG. 1, stevioside (Tum-Ste), rebaudioside (Tum-RebA) and steviol glycoside (Tum-SG) were mixed with ethanol , It was confirmed that the water-soluble solvent, water, was well dissolved in water.
<< 실험예Experimental Example 2> 크로마토그래피 측정 2> Chromatographic measurement
에탄올을 증발시키고 남은 울금 가루를 수용성 용매로서 1 ㎖ 증류수(Tum-Ste, Tum-RebA, Tum-SG의 경우)에 녹이고, 12,000 rpm 으로 10 분 동안 원심분리하고, 맑은 상등액은 0.20 ㎛ membrane 필터(Agilent, Santa clara, CA, USA)를 이용하여 상층의 용액만 회수하여 용매을 증발시켜서 용해도가 증가된 커큐민을 수득하였다.Ethanol was evaporated and the remaining ugly powder was dissolved in 1 ml of distilled water (for Tum-Ste, Tum-RebA and Tum-SG) as a water-soluble solvent and centrifuged at 12,000 rpm for 10 minutes. The clear supernatant was filtered through a 0.20 ㎛ membrane filter Agilent, Santa Clara, Calif., USA), and the solvent was evaporated to obtain an increased solubility of curcumin.
상기와 같이 얻어진 커큐민이 수용액에 대한 용해도가 증가되었는지 여부를 관찰하기 위하여 얇은막 크로마토그래피(TLC)를 수행하였다. 전개용매로는 acetonitrile/water 85:15 (v/v)을 이용하여 UV254mm 파장에서 확인하고, TLC plate를 다시 메탄올에 0.5 (w/v) N-(1-Naphthy) ethylenediamine dihydrochloride 와 5% (w/v) sulfuric acid 를 녹여 준비한 발색 시약에 담근 후 90℃에서 3 min 간 처리하였다. Thin film chromatography (TLC) was performed to observe whether the curcumin obtained as described above had increased solubility in an aqueous solution. The TLC plate was re-dissolved in methanol at a ratio of 0.5 (w / v) N- (1-Naphthy) ethylenediamine dihydrochloride and 5% (w / v) at a UV 254 mm wavelength using acetonitrile / water 85:15 / v) sulfuric acid was dissolved in the prepared coloring reagent and treated at 90 ° C for 3 min.
그 결과, 도 2에서 보는 바와 같이 에탄올 처리 후 수용성이 증가된 물질이 확인되었으며, 스테비올 배당체, 리바우디오사이드 A 또는 스테비오사이드를 에탄올과 함께 처리한 경우 에탄올 만을 처리한 경우에 비해 수용화가 더욱 증가한다는 것이 확인되었다 (도 2). (Lane 1: Tum-Ethanol, Lane2: Tum-Ste, Lane 3: Tum-RebA, Lane 4: Tum-SG)As a result, as shown in FIG. 2, it was confirmed that the water-soluble substance was increased after the ethanol treatment, and when the steviol glycosides, ribauidoside A or stevioside were treated with ethanol, (Fig. 2). (Lane 1: Tum-Ethanol, Lane 2: Tum-Ste, Lane 3: Tum-Reba, Lane 4: Tum-SG)
<< 실시예Example 2> 용액 농도에 따른 2> Depending on solution concentration 커큐미노이드의Cucuminoid 추출 효율 비교 Comparison of extraction efficiency
실시예 1에서 울금 가루와 같이 스테비오사이드, 리바우디오사이드 및 스테비올 배당체 혼합물에 넣어준 에탄올 용액의 농도에 따라서 최종 얻어진 수용화된 추출물에 들어 있는 커큐미노이드의 양과 추출 수율을 하기 식1을 통해 계산하고 그 결과를 표 1에 나타내었다. The amount of glucuronide contained in the final obtained aqueous extract and the extraction yield according to the concentration of the ethanol solution put into the mixture of stevioside, rebaudioside and steviolglycoside, as in the case of Example 1, And the results are shown in Table 1. < tb > < TABLE >
식 1
(%, v/v)The amount of water during the ripening process *
(%, v / v)
(mg/g turmeric extraction)Acceptable cacuminoids using stevioside
(mg / g turmeric extraction)
(mg/g turmeric extraction)Aqueous cocumidolide using rebaudioside
(mg / g turmeric extraction)
(mg/g turmeric extraction)Aqueous cucuminoids using steviol glycoside
(mg / g turmeric extraction)
*: 울금 가루와 스테비올 배당체의 혼합물에 첨가되는 에탄올 용액 중 물의 양을 나타낸다 (예를 들면, 물 0%는 100% 에탄올을 사용하였고, 물 80%는 20% 에탄올을 사용하였다). *: Represents the amount of water in the ethanol solution added to the mixture of ugly powder and steviol glycoside (for example, 0% water used 100% ethanol and 80% water used 20% ethanol).
그 결과, 스테비오사이드를 이용하여 커큐미노이드를 추출할 때는 사용되는 물의 함량을 최소화할수록 추출 수율이 높아지며, 리바우디오사이드는 10%의 물을 포함할 때(즉, 90% 에탄올 용액을 사용할 때), 및 스테비올 배당체도 10 내지 20%의 물을 포함할 때(즉, 80% 내지 90% 에탄올 용액을 사용하는 경우) 추출 수율이 가장 좋은 것으로 나타났다. As a result, when extracting the glucuronide using stevioside, the extraction yield is increased as the water content is minimized. When the rubaidoside contains 10% water (that is, when 90% ethanol solution is used ), And steviol glycosides also contained 10 to 20% water (i.e., 80% to 90% ethanol solution was used).
울금의 추출을 위해 사용된 3가지 추출용 소재 중에서는 스테비오사이드가 가장 좋은 수율을 보여주는 것으로 나타났다(도 3).Among the three extractive materials used for the extraction of ugum, stevioside showed the best yield (Fig. 3).
<< 실시예Example 3> 스테비올 배당체의 첨가농도에 따른 3> Depending on the concentration of steviol glycosides 커큐미노이드의Cucuminoid 추출 효율 비교 Comparison of extraction efficiency
실시예 1에서 울금 추출시 혼합되는 스테비올 배당체의 혼합 비율에 따른 수용화된 커큐미노이드의 양을 계산하고 그 결과를 표 2에 나타내었다. The amount of cupricuminolide was calculated according to the mixing ratio of the steviol glycosides mixed in the extraction of the urogens in Example 1, and the results are shown in Table 2.
(%, v/v)Concentration of steviol glycosides
(%, v / v)
(mg/g turmeric extraction)Acceptable cacuminoids using stevioside
(mg / g turmeric extraction)
(mg/g turmeric extraction)Aqueous cocumidolide using rebaudioside
(mg / g turmeric extraction)
(mg/g turmeric extraction)Aqueous cucuminoids using steviol glycoside
(mg / g turmeric extraction)
그 결과, 스테비오사이드, 리바우디오사이드 및 스테비올 배당체 모두 동일 조건하에서 8%의 농도로 사용할 때 수용화 수율이 가장 좋은 것으로 확인되었다(도 4).As a result, it was confirmed that the stiboside, ribeodioxide and steviol glycoside both had the best water-soluble yield when used at the concentration of 8% under the same conditions (Fig. 4).
<< 실시예Example 4> 4> 울금의Ulgum 농도에 따른 Depending on concentration 커큐미노이드의Cucuminoid 추출 효율 비교 Comparison of extraction efficiency
실시예 1에서 울금 추출시 에탄올에 용해되는 울금의 농도에 따른 수용화된 커큐미노이드의 양을 계산하고 그 결과를 표 3에 나타내었다. In Example 1, the amount of cucuminoids hydrated was calculated according to the concentration of cucumber dissolved in ethanol at the time of cucumber extraction, and the results are shown in Table 3.
(%, v/v)Ugly concentration
(%, v / v)
수용화 커큐미노이드Use StevioSide
Aqueous cocuminoid
수용화 커큐미노이드Use Ribau dioside
Aqueous cocuminoid
수용화 커큐미노이드Using steviol glycosides
Aqueous cocuminoid
다른 조건이 동일할 경우 스테비오사이드, 리바우디오사이드 및 스테비올 배당체 모두 에탄올에 첨가되는 울금의 농도가 1% 일 때 수용화 수율이 가장 좋은 것으로 나타났다(도 5). When the other conditions were the same, the stevioside, rebaudioside, and steviol glycosides both had the highest water solubility yields when the concentration of ugum added to ethanol was 1% (Fig. 5).
한편, 에탄올에 첨가되는 울금의 농도가 30-35%인 경우 가장 많은 양의 커큐미노이드가 추출되었으며, 에탄올에 첨가되는 울금의 농도가 35%를 넘는 경우 울금의 농도 증가에 따른 커큐미노이드의 추출량에 있어서 유의적인 차이가 존재하지 않았다(도 6). On the other hand, the highest amount of curcuminoids was extracted at 30-35% concentration of cucuminoids added to ethanol, and when the concentration of cucurbitides added to ethanol was higher than 35% There was no significant difference in the extraction amount (FIG. 6).
<< 실험예Experimental Example 3> 추출된 3> extracted 커큐미노이드의Cucuminoid 항산화 특성 Antioxidant properties
상기 실시예를 통해 추출된 커큐미노이드의 생리적 특성을 확인하기 위하여 DPPH 라디칼 소거활성(DPPH radical-scavenging activity) 측정 실험을 수행하였다. DPPH radical scavenging activity (DPPH radical scavenging activity) experiments were conducted to confirm the physiological characteristics of the glucuronides extracted through the above examples.
DPPH 라디칼 소거활성은 업계에 공지된 방법에 따라 측정하였다. DPPH 용액(45㎍/㎖ methanol)을 상기 실시예에서 얻어진 추출물과 혼합한 다음 515㎚에서 30초 간격으로 3분간 흡광도의 감소를 측정하였다. The DPPH radical scavenging activity was measured according to methods known in the art. DPPH solution (45 占 퐂 / ml methanol) was mixed with the extract obtained in the above example, and the decrease in absorbance was measured at 515 nm for 30 minutes at intervals of 30 seconds.
라디칼 소거활성은 비타민-C의 흡광도 감소를 100% 로 기준하여 계산하였으며, DPPH의 흡광도가 50% 감소할 때 나타나는 시료의 농도를 IC50으로 표시하여 아래 표 4 및 도 7에 나타내었다. The radical scavenging activity was calculated based on 100% reduction of the absorbance of vitamin C, and the concentration of the sample when the absorbance of DPPH was reduced by 50% is indicated by IC 50 , and is shown in Table 4 and FIG.
상기 표 4에서 보는 바와 같이 일반적으로 커큐미노이드는 수용화가 거의 되지 않는 것과 달리 스테비오사이드, 리바우디오사이드 및 스테비올 배당체로 추출한 수용화된 커큐미노이드는 항산화 활성을 나타냈으며, 특히 도 7에서 보는 바와 같이 스테비오사이드로 추출한 커큐미노이드의 경우 DMSO에 녹인 커큐민보다 유사하거나 다소 향상된 수준의 항산화 특성을 나타낸다는 것이 확인되었다. As shown in Table 4, the cacuminoids generally showed almost no hydroxylation, whereas the water-soluble cacuuminoids extracted with steviosides, ribaudiosides and steviolglycosides showed antioxidative activities, As can be seen, it was confirmed that the glucoside extracted from stevioside exhibited similar or somewhat improved antioxidant properties to curcumin dissolved in DMSO.
<< 실험예Experimental Example 4> 수용성이 4> water soluble 증가된Increased 커큐미노이드의Cucuminoid 항산화 특성 분석 Antioxidant characterization analysis
울금 분말에서 직접 추출한 수용성 울금 추출물의 항산화 활성은 2,2-diphenyl-1-picrylhydrazyl (DPPH) 라디칼 소거능 방식으로 확인하였다. 각 시료는 100 ㎛(DPPH)에 최종 농도가 10 ~ 500 ㎍이 되도록 물에 녹였다. 25°C에서 30분간 암실 보관 후 517 nm 로 microplate reader (Molecular Devices, Sunnyvale, CA, USA)를 이용하여 농도를 확인하였다. Curcuminoids (≥ 94%), α-tocopherol, trolox 를 양성표준물로 이용하였고, DPPH radical-scavenging activity 는 하기 식2로 결정하고 그 결과를 도 8에 나타내었다. The antioxidative activity of water extracts from water extracts from uleum powder was confirmed by 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging method. Each sample was dissolved in water to a final concentration of 10 ~ 500 ㎍ in 100 ㎛ (DPPH). After incubation at 25 ° C for 30 minutes, the concentration was determined at 517 nm using a microplate reader (Molecular Devices, Sunnyvale, CA, USA). Curcuminoids (≥ 94%), α-tocopherol, and trolox were used as positive standards, and the DPPH radical-scavenging activity was determined by the
식 2
도 8에서 Ste, RebA, 그리고 SG로 수용화한 커큐미노이드의 SC50 값은 각각 127.6 ± 4.9, 105.4 ± 1.8, 그리고 109.8 ± 3.2 ㎍/㎖ 로 측정되었고, 비교군으로 사용한 Curcuminoids (≥≥ 94%), α-tocopherol, 그리고 trolox의 SC50 값은36.2 ± 2.6 ㎍/㎖, 3.5 ± 0.1, 그리고 8.4 ± 0.1 ㎍/㎖로 측정되어 본 발명에 의하여 추출된 수용성 커큐미노이드의 항산화 활성이 크게 증가된 것을 알 수 있다. In Fig. 8, the SC 50 values of the cucuminizoids hydrolyzed with Ste, RebA and SG were measured as 127.6 ± 4.9, 105.4 ± 1.8, and 109.8 ± 3.2 ㎍ / ㎖, respectively, and Curcuminoids (≥≥ 94 %), α-tocopherol, and SC 50 value for trolox is a 36.2 ± 2.6 ㎍ / ㎖, 3.5 ± 0.1, and 8.4 ± measured in 0.1 ㎍ / ㎖ antioxidant activity of the water-soluble larger kyumi extracted by the present invention cannabinoids significantly , Respectively.
<< 실험예Experimental Example 5> 추출된 수용성 5> extracted water solubility 커큐미노이드의Cucuminoid pH 안정성 확인 Check pH stability
상기 실시예 1에서 추출된 수용성 커큐미노이드의 pH에 따른 안정성을 pH 6 ~ 10 조건에서 확인하였다. (사용 완충액: 50 mM Na-P - pH 6.0, pH 7.0, pH 7.5; NaOH-glycin - pH 8.0 ~ pH 10.0). 상기 실시예 1에서 추출된 2 ㎍의 커큐미노이드를 각각 pH 6 ~ 10에 녹여 25 ℃에서 1주일간 보관하고 12,000g로 10 분간 원심분리하여 상등액을 0.20 ㎛ membrane으로 필터링하고, 수용성 커큐미노이드의 양을 확인하였다. 커큐미노이드 양은 425 nm에서 흡광도를 측정하여 확인하거나 TLC method 를 이용하여 결정하였다. The stability of the aqueous soluble glucuronidase extracted from Example 1 according to pH was confirmed at
pH 6.0에서 남아 있는 양에 비례한 상대적 양은 각각 80.3 ± 0.4, 81.6 ± 0.9, 그리고 82.3 ± 2.4 % 였다. The relative amounts in proportion to the remaining amount at pH 6.0 were 80.3 ± 0.4, 81.6 ± 0.9, and 82.3 ± 2.4%, respectively.
본 발명에 의하여 추출된 수용화된 커큐미노이드는 pH가 7이상 되어도 84% 이상 유지가 되고 있어 다양한 pH에서 안정함을 확인하였다. 또한, 본 발명에서 제조된 수용화된 커큐미노이드는 넓은 pH의 수용액 내에서 안정함을 확인하였다. The water-soluble glucuronidase extracted by the present invention was maintained at 84% or more even when the pH was 7 or higher, and was stable at various pH values. In addition, it was confirmed that the water-soluble cucuminoids prepared in the present invention were stable in aqueous solutions having a wide pH.
<< 실험예Experimental Example 6> 6> 수용화한Encapsulated 커큐미노이드의Cucuminoid 입자 크기 분석 Particle size analysis
수용화한 커큐미노이드 복합체 (스테비오사이드 등과의 복합체)의 입자 크기를 분석하기 위해서 상기 실시예 1에서 제조된 스테비오사이드, 리바우디오사이드, 스테비올글루코사이드 커큐미노이드-스테비오사이드 복합체 (Tum-Ste), 커큐미노이드-리바우디오사이드 복합체 (Tum-RebA), 및 커큐미노이드-스테비올 글루코사이드 복합체 (Tum-SG)10 mg 를 10 ㎖ 물에 녹였다. Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, UK)를 이용하여 동적광산란(Dynamic light scattering, DLS)을 확인하여 각 소재들의 입자 크기를 결정하였다. To analyze the particle size of the encapsulated cucuminoid complex (complex with stevioside etc.), the stevioside, ribauidoside, steviol glucoside cucuminoid-stevioside complex (Tum-Ste ), Cucuminoid-rebaudioside complex (Tum-RebA), and cucuminoid-steviol glucoside complex (Tum-SG) were dissolved in 10 ml of water. Dynamic light scattering (DLS) was confirmed using a Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, UK) to determine the particle size of each material.
Ste, RebA, SG로 수용화된 울금분말 추출물과 에탄올로 추출한 울금 분말 추출물 그리고 스테비오사이드, 리바우디오사이드 그리고 스테비올 글루코사이드의 입자 크기 측정 결과는 도 9와 같았다. Fig. 9 shows the results of measuring the particle size of the urophyllum powder, which was hydrolyzed with Ste, RebA and SG, the urophyllum powder extracted with ethanol, and the steviosides, ribaudioside and steviol glucoside.
도 9 에서 보는 바와 같이 Ste, RebA, 그리고 SG 입자 크기는 각각 2.4 nm, 3.35 nm, 그리고 2.6 nm 이고, 에탄올만으로 추출한 추출물, Ste, RebA, 그리고 SG 로 추출한 추출물의 입자 크기는 각각 2.0 nm, 110.8 nm, 95.7 nm, 및 32.7 nm 로 측정되어 본 발명에 따라 수용화된 커큐미노이드는 입자 크기가 30 내지 120 nm 의 범위로 입자 사이즈가 나노 사이즈로 생체이용성이 증가될 것으로 판단된다. As shown in FIG. 9, the particle sizes of Ste, RebA and SG were 2.4 nm, 3.35 nm and 2.6 nm, respectively, and the particle sizes of extracts extracted with ethanol alone, Ste, RebA and SG were 2.0 nm and 110.8 nm, 95.7 nm, and 32.7 nm, the cupose size according to the present invention is considered to be bioavailable with a particle size of 30 to 120 nm and a particle size of nanosize.
<< 실험예Experimental Example 7> 7> 수용화된Aqueous 커큐미노이드의Cucuminoid 혈당 상승 억제 특성 Blood sugar increase inhibition characteristic
실험동물은 6주령 수컷 Sprague-Dawley(SD) rat을 구입하여 습도 50%, 온도 22±1℃로 유지되는 동물실험실에서 1주일간 적응시켰으며, 실험 전 16시간 동안 절식시킨 후 체중 1kg을 기준으로 1g 말토오스를 주사로 복강 투여 후 체중 1kg을 기준으로 0.75 mg Tum-Ste, 10 mg 스테비오사이드를 투여하였으며 시간 별로 꼬리 정맥에서 채혈된 전혈을 혈당측정기로 측정하였다. 대조군은 물을 투여하였다. 측정된 혈당의 변화를 확인하고 그 결과를 도 10에 나타내었다.Male Sprague-Dawley (SD) rats were purchased from a 6-week-old male rats and were adapted for 1 week in an animal laboratory maintained at a humidity of 50% and a temperature of 22 ± 1 ° C. After fasting for 16 hours before the experiment, After 1 g of maltose was injected intraperitoneally, 0.75 mg of Tum-Ste and 10 mg of stevioside were administered based on 1 kg of body weight. Whole blood collected from the tail vein was counted with a glucose meter. The control group was administered with water. The change in the measured blood glucose was confirmed and the results are shown in Fig.
도 10을 참조하면 말토오스가 투여되고 15 내지 30분간 혈당치가 급격히 상승하며, 스테비올 배당체를 투여한 경우에는 큰 변화는 나타나지 않았으나, 스테비올 배당체로 추출한 커큐미노이드(Tum-SG)가 투여된 군은 혈당치의 상승이 매우 완화되었으며 지속적으로 혈당을 일정수준으로 유지시키는 것으로 나타났다. 이를 통해 스테비오사이드로 추출한 커큐미노이드의 경우 수용화된 커큐민이 탁월한 수준의 혈당상승 억제 특성을 나타낸다는 것이 확인되었다. Referring to FIG. 10, when maltose was administered and blood glucose level rapidly increased for 15 to 30 minutes, no significant change was observed when the steviol glycosides were administered, but when glucuronide (Tum-SG) Showed that the rise in blood sugar level was greatly eased and the blood glucose level was maintained constantly. It was confirmed that curcuminoids extracted with stevioside showed an excellent level of glucose uptake inhibition by water - soluble curcumin.
<< 실험예Experimental Example 8> 8> 수용화된Aqueous 커큐미노이드의Cucuminoid 뎅기열 바이러스( Dengue virus ( DENV4DENV4 )의 )of NS2BNS2B -- NS3NS3 propro 활성 저해 특성 Activity inhibition characteristic
재조합 DENV4 NS2B-NS3pro 효소를 준비하고 (In vitro evaluation of novel inhibitors against the NS2B-NS3 protease of dengue fever virus type 4. Molecules, 18, 15600-15612) 수용성 울금 추출물의 농도를 1 ~ 200 ㎍/㎕으로 하여 NS2B-NS3pro 에 대한 활성 저해 특성을 확인하였다. 최종 효소반응기 100 ㎕ 에 0.04 U enzymes, 1.65 ㎛ 형광 tetrapeptide substrate[benzoyl-norleucine-lysine-arginine-arginine-7-amino-4-methyl coumarin (AMC) (Bachem, Bubendorf, Switzerland)], 2 ㎕ 의 저해 시험 소재, 그리고 40 mM Tris buffer (pH 7.5)를 넣어주었다. 저해 시료에 따른 남은 효소의 최종 활성은 SpectraMax Gemini XPS apparatus (Molecular Devices, Sunnyvale, CA, USA) (λex = 380 nm, λem = 460 nm) 를 이용하여 확인하였다. Curcuminoids (순도 ≥ 94%)를 positive control로 사용하였다. The recombinant DENV4 NS2B-NS3 pro enzyme was prepared ( in vitro evaluation of novel inhibitors against the NS2B-NS3 protease of
저해 정도는 하기 식 3으로 결정하였다. The degree of inhibition was determined by the following
식 3
C - (enzyme, buffer, 효소 substrate 혼합액)의 20분 반응 후 의 컨트롤, Control after 20 minutes reaction of C - (enzyme, buffer, enzyme substrate mixture)
C o - 0 시간에서의 컨트롤의 형광, C o - Fluorescence of the control at 0 hours,
S - (enzyme, 테스트 시료, 효소 substrate 혼합액)의 20분 반응 후 형광, After 20 min of S - (enzyme, test sample, enzyme substrate mixture), fluorescence,
S o - (enzyme, 테스트 시료, 효소 substrate 혼합액)의 반응 전 형광. S o - Fluorescence before reaction of (enzyme, test sample, enzyme substrate mixture).
IC50 은 저해제 없을 때의 NS2B-NS3pro 활성을 50% 낮출 수 있는 소재의 농도. IC 50 is the concentration of material that can lower the activity of NS2B-NS3 pro by 50% in the absence of inhibitor.
도 11에서 보는 바와 같이 Ste, RebA 와 SG로 준비 한 수용화된 울금 추출물의 뎅기 바이러스의 NS2B-NS3pro 단백질 분해 효소에 대한 저해 특성을 확인 하였고, IC50 값은 각각 14.1 ± 0.2, 24.0 굇 0.4, 그리고 15.3 ± 0.4 ㎍/㎖ 로 확인되었다. As shown in FIG. 11, inhibition of dengue virus against the NS2B-NS3 pro protease was confirmed by the use of Steer, RebA and SG, and the IC 50 values were 14.1 ± 0.2 and 24.0 굇 0.4 , And 15.3 ± 0.4 ㎍ / ㎖, respectively.
비교예로 사용한 DMSO 에 용해시킨 커큐미노이드 비교군은 IC50 값이 5.2 ㎍/㎖ 로 본원 발명의 수용화된 울금 추출물의 뎅기 바이러스의 NS2B-NS3pro 단백질 분해 효소에 대해 저해 활성을 나타내는 것을 확인할 수 있다. Comparison was increased kyumi dissolved in DMSO used in Example solenoid control group is confirmed that the IC 50 value represents a 5.2 ㎍ / ㎖ inhibitory activity for NS2B-NS3 pro protease of dengue virus of a receiving screen turmeric extract of the present invention to .
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.The present invention has been described with reference to the preferred embodiments. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.
Claims (10)
(ii) 상기 혼합물을 에탄올에 용해시키는 단계;
(iii) 원심분리시키는 단계;
(iv) 상층액을 분리 제거하는 단계; 및
(v) 분리된 상층액에 포함된 에탄올을 제거하는 단계; 를 포함하는
스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법
(i) mixing a raw material containing curcumin and a steviol glycoside;
(ii) dissolving the mixture in ethanol;
(iii) centrifuging;
(iv) separating and removing the supernatant; And
(v) removing ethanol contained in the separated supernatant; Containing
Extraction of cucuminoids with increased solubility using steviol glycosides
상기 커큐민 포함 원재료는 울금 또는 강황인 것인
스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법
The method according to claim 1,
The curcumin-containing raw material may be selected from the group consisting of < RTI ID = 0.0 >
Extraction of cucuminoids with increased solubility using steviol glycosides
상기 스테비올 배당체는 스테비오사이드(stevioside), 리바우디오사이드 A, 리바우디오사이드 B, 리바우디오사이드 C, 리바우디오사이드 D, 리바우디오사이드 E, 루부소사이드, 둘코사이드 A, 스테비올사이드 및 이들의 혼합물로 이루어진 그룹에서 선택되는 것인
스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법
The method according to claim 1,
Wherein the steviol glycoside is selected from the group consisting of stevioside, ribauidoside A, ribauidoside B, ribauidoside C, ribauidoside D, ribauidoside E, rubusoide, dulcoside A, ≪ / RTI > and mixtures thereof. ≪ RTI ID = 0.0 >
Extraction of cucuminoids with increased solubility using steviol glycosides
상기 커큐민 포함 원재료와 스테비올 배당체의 혼합물을 에탄올에 용해시 상기 스테비올 배당체의 농도는 5-10% (w/v)인 것인
스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법
The method according to claim 1,
When the mixture of the curcumin-containing raw material and the steviol glycoside is dissolved in ethanol, the concentration of the steviol glycosides is 5-10% (w / v)
Extraction of cucuminoids with increased solubility using steviol glycosides
상기 커큐민 포함 원재료와 스테비올 배당체의 혼합물을 에탄올에 용해시 상기 스테비올 배당체는 정제된 것이거나 효소 반응산물인 것인
스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법
The method according to claim 1,
When the mixture of the curcumin-containing raw material and the steviol glycoside is dissolved in ethanol, the steviol glycosides are purified or enzymatic reaction products
Extraction of cucuminoids with increased solubility using steviol glycosides
상기 커큐민 포함 원재료와 스테비올 배당체의 혼합물을 에탄올에 용해시 상기 에탄올의 농도는 80 내지 90 % 인 것인
스테비올 배당체를 이용한 수용성이 증가된 커큐미노이드의 추출 방법
The method according to claim 1,
When the mixture of the curcumin-containing raw material and the steviol glycosides is dissolved in ethanol, the concentration of the ethanol is 80 to 90%
Extraction of cucuminoids with increased solubility using steviol glycosides
A process for the preparation of a glucuronidase having increased water-soluble glucuronide extracted by a method of extracting a glucuronidase from a steviol glycoside according to any one of claims 1 to 6
상기 커큐미노이드의 입자 크기는 2 내지 120 nm 인 것인
스테비올 배당체를 이용하여 추출된 수용성이 증가된 커큐미노이드
8. The method of claim 7,
Wherein the particle size of the glucoside is from 2 to 120 nm
The increased water-soluble cucuminoids extracted with steviol glycosides
상기 커큐미노이드는 혈당 상승 저해 특성을 나타내는 것인
스테비올 배당체를 이용하여 추출된 수용성이 증가된 커큐미노이드
8. The method of claim 7,
The curcuminoid exhibits the blood glucose-raising inhibitory properties
The increased water-soluble cucuminoids extracted with steviol glycosides
상기 커큐미노이드는 뎅기열 바이러스의 활성 저해 특성을 나타내는 것인
스테비올 배당체를 이용하여 추출된 수용성이 증가된 커큐미노이드
8. The method of claim 7,
The curcuminoids exhibit the inhibitory activity against Dengue fever virus
The increased water-soluble cucuminoids extracted with steviol glycosides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160046012 | 2016-04-15 | ||
KR1020160046012 | 2016-04-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170118624A true KR20170118624A (en) | 2017-10-25 |
KR101924159B1 KR101924159B1 (en) | 2018-11-30 |
Family
ID=60300109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170049391A KR101924159B1 (en) | 2016-04-15 | 2017-04-17 | Method for extracting soluble curcuminoid from turmericand soluble curcuminoid extracted by the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101924159B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102350473B1 (en) * | 2018-03-23 | 2022-01-11 | 한국생명공학연구원 | Composition for Improving Bowel Function or Increasing Intestinal Microbes |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011047227A2 (en) | 2009-10-15 | 2011-04-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Water soluble drug-solubilizer powders and their uses |
KR101436464B1 (en) | 2011-07-29 | 2014-09-01 | 한국생명공학연구원 | Composite comprising steviol glycoside or licorice, and poorly soluble agent |
-
2017
- 2017-04-17 KR KR1020170049391A patent/KR101924159B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR101924159B1 (en) | 2018-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nguyen et al. | Facile preparation of water soluble curcuminoids extracted from turmeric (Curcuma longa L.) powder by using steviol glucosides | |
US20230132001A1 (en) | Immunity-boosting agent, immuno-therapeutic anti-cancer agent, and anti-cancer therapy adverse effect mitigating agent containing anthocyanin-fucoidan complex as active ingredient | |
Conde et al. | Extraction of natural antioxidants from plant foods | |
KR101440684B1 (en) | Novel antioxidative peptide purified from a marine Chlorella ellipsoidea. | |
KR20240032795A (en) | Antioxidative composition having improved stability | |
KR101924159B1 (en) | Method for extracting soluble curcuminoid from turmericand soluble curcuminoid extracted by the same | |
KR101616811B1 (en) | Composition for treating diabete and diabete-induced complication containing an extract from Agrimonia pilosa | |
KR101630782B1 (en) | Glucosinolate Compound from Broccoli and Composition Having Antioxidant and Antimicrobial Activity Comprising the Same | |
KR101927404B1 (en) | Liquid composition comprising compound K at high concentration and producing method thereof | |
KR20170129002A (en) | Composition for Anti-oxidation Containing Purified Fraction of Ginseng berry Extract | |
KR102604237B1 (en) | Composition for enhancing the bioavailability of fat-soluble vitamins | |
KR20190070569A (en) | Composition for anti-oxidant, skin whitening and anti-wrinkle effect comprising Glehnia Radix leaf extract as effective component | |
Onsrisawat et al. | Hepatoprotective and antioxidant properties of Schizophyllum commune fruiting body | |
US8124137B2 (en) | Composition for prevention and/or treatment of tumors containing acacia bark derivative | |
KR102214014B1 (en) | Antioxidant or anticancer composition comprising extract of Osmanthus heterophylla leaf | |
KR101440483B1 (en) | Composition for antiaging comprising extract or fraction of Ardisia tinctoria Pit. as an active ingredient | |
Pratami et al. | Comparison of Total Phenolic Content and Antioxidant Activity of Indonesian Propolis Extracted with Various Solvents. | |
KR101068699B1 (en) | Composition for antioxidation effect comprising sparassis crispa extract | |
KR20110126413A (en) | Composition for antioxidant and anticancer activity containing seanol and fucoidan from ecklonia cava | |
JP3575766B2 (en) | Functional food | |
KR20120111221A (en) | A pharmaceutical composition comprising blackberry extract for protecting liver | |
KR101620007B1 (en) | Composition for treating or preventing cancer containing extract of cladosiphon novae-caledoniae kylin | |
Madan | Effect of extraction solvents on total phenolics and flavonoids contents of Capparis deciduas (Forsk.) Edgew flowers and its nutritional potential | |
KR20210058164A (en) | Method for Producing Agrimony Extract, and Composition for Improving Liver Function or Treating Liver Desease Containing the Same | |
KR101319552B1 (en) | Compositions for prevention or treatment of diabetes mellitus or diabetic complications containing stings of Gleditsia sinensis extracts as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |